Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees

Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees

BackgroundResidents of nursing homes are one of the most vulnerable groups during the severe acute syndrome coronavirus 2 (SARS-CoV-2) pandemic. The aim of this study was to characterize cellular and humoral immune responses in >70-year-old participants before vaccination, after first and sec...

Full description

Bibliographic Details
Main Authors:	Michael Jäger, Sissy Therese Sonnleitner, Stefanie Dichtl, Eliott Lafon, Gabriel Diem, Gernot Walder, Cornelia Lass-Flörl, Doris Wilflingseder, Wilfried Posch
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-06-01
Series:	Frontiers in Immunology
Subjects:	Age-dependent immune responses after BNT162b2 SARS-CoV-2 vaccination T cell immunity neutralizing antibodies SARS-CoV-2 variants of concern (VOCs)
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.868361/full

Similar Items

Omicron (B.1.1.529) BA.1 or BA.2-related effects on immune responses in previously naïve versus imprinted individuals: immune imprinting as an advantage in the humoral immune response against novel variants
by: Sissy Therese Sonnleitner, et al.
Published: (2023-05-01)

Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents
by: Naomi S. Coombes, et al.
Published: (2023-02-01)

Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees
by: Gabriele Anichini, et al.
Published: (2022-05-01)

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
by: Evangelos Terpos, et al.
Published: (2021-07-01)

Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults
by: Jonas Herzberg, et al.
Published: (2022-05-01)

Impact of BNT162b2 Booster Dose on SARS-CoV-2 Anti-Trimeric Spike Antibody Dynamics in a Large Cohort of Italian Health Care Workers
by: Laura V. Renna, et al.
Published: (2023-02-01)

Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort studyResearch in context
by: Line Dam Heftdal, et al.
Published: (2023-07-01)

Antibody response after two doses of the BNT162b2 vaccine among healthcare workers of a Greek Covid 19 referral hospital: A prospective cohort study
by: Areti Tychala, et al.
Published: (2022-05-01)

Comparative Study of T-Cell Repertoires after COVID-19 Immunization with Homologous or Heterologous Vaccine Booster
by: Elizabeth-Barbara Tatsi, et al.
Published: (2024-03-01)

Specific immune responses after BNT162b2 mRNA vaccination and COVID-19 infection
by: Simona Arientová, et al.
Published: (2023-10-01)

Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
by: Napaporn Chantasrisawad, et al.
Published: (2022-05-01)

Long-Term Analyses of SARS-CoV-2 Humoral and T Cell Responses and Breakthrough SARS-CoV-2 Infections after Two Doses of BNT162b2 Followed by mRNA-1273 and Bivalent Omicron-Adapted BNT162b2 Vaccines: A Prospective Study over 2 Years in Non-Immunocompromised Individuals
by: Alejo Erice, et al.
Published: (2023-12-01)

BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
by: Abbass Darwich, et al.
Published: (2022-04-01)

Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection
by: Theano Lagousi, et al.
Published: (2022-07-01)

Levels of Neutralizing Antibodies against SARS-CoV-2 in Mothers and Neonates after Vaccination during Pregnancy
by: Antônio Oliveira da Silva Filho, et al.
Published: (2023-03-01)

Antibody responses to BNT162b2 SARS‐CoV‐2 mRNA vaccine among healthcare workers and residents of long‐term care facilities: A cohort study in Northern Italy
by: Costanza Vicentini, et al.
Published: (2023-02-01)

Kinetics of SARS-CoV-2 Spike Antibodies after the Second and Third Dose of the BNT162b2 COVID-19 Vaccine and Association with Epidemiological Characteristics and Breakthrough Infection in a Cohort Study of Healthcare Workers
by: Elizabeth-Barbara Tatsi, et al.
Published: (2023-08-01)

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study
by: Rafaella F. Q. Grenfell, et al.
Published: (2022-06-01)

Immunogenicity of an mRNA-Based COVID-19 Vaccine among Adolescents with Obesity or Liver Transplants
by: Chomchanat Tubjaroen, et al.
Published: (2022-11-01)

Impact of Full Vaccination with mRNA BNT162b2 on SARS-CoV-2 Infection: Genomic and Subgenomic Viral RNAs Detection in Nasopharyngeal Swab and Saliva of Health Care Workers
by: Michela Deiana, et al.
Published: (2021-08-01)

Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2
by: Jean-Louis Bayart, et al.
Published: (2021-06-01)

BNT162b2 Vaccination after SARS-CoV-2 Infection Changes the Dynamics of Total and Neutralizing Antibodies against SARS-CoV-2: A 6-Month Prospective Cohort Study
by: Jorge Hernández-Bello, et al.
Published: (2023-06-01)

Systemic COVID-19 Vaccination Enhances the Humoral Immune Response after SARS-CoV-2 Infection: A Population Study from a Hospital in Poland Criteria for COVID-19 Reimmunization Are Needed
by: Piotr Kosiorek, et al.
Published: (2022-02-01)

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
by: Chin Shern Lau, et al.
Published: (2022-11-01)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
by: Chaitanya Kurhade, et al.
Published: (2022-12-01)

Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
by: Jessica J. Tuan, et al.
Published: (2022-09-01)

Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA
by: Eva Piano Mortari, et al.
Published: (2021-09-01)

Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant
by: Irene Cassaniti, et al.
Published: (2021-12-01)

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
by: Evangelos Terpos, et al.
Published: (2021-10-01)

Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection
by: Blanka Wolszczak-Biedrzycka, et al.
Published: (2021-12-01)

Molecular Mimicry and HLA Polymorphisms May Drive Autoimmunity in Recipients of the BNT-162b2 mRNA Vaccine: A Computational Analysis
by: Rossella Talotta
Published: (2023-06-01)

Long COVID and Hybrid Immunity among Children and Adolescents Post-Delta Variant Infection in Thailand
by: Muttharat Jarupan, et al.
Published: (2023-04-01)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
by: Evangelos Terpos, et al.
Published: (2022-02-01)

Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine – A Prospective Observational Study
by: Jonas Herzberg, et al.
Published: (2022-07-01)

Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
by: Thanyawee Puthanakit, et al.
Published: (2022-09-01)

Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5
by: Gabriel Diem, et al.
Published: (2023-06-01)

Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine
by: Claudia Gandolfo, et al.
Published: (2022-01-01)

Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents
by: Pavinee Assavavongwaikit, et al.
Published: (2022-07-01)

Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines
by: George Kassianos, et al.
Published: (2024-01-01)

Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: A prospective longitudinal cohort study
by: Erika Molteni, et al.
Published: (2022-08-01)